What are Corcept Therapeutics's profit margins?

Corcept Therapeutics (CORT) runs a 98.3% gross margin and a -1.1% operating margin, with a 6.2% net margin.

Where do Corcept Therapeutics's ratios come from?

Every ratio is computed from Corcept Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Corcept Therapeutics CORT Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	98.3%-0.1pp	98.4%-0.3pp	98.7%0.0pp	98.7%+0.1pp
Operating margin	5.9%-14.4pp	20.3%-2.0pp	22.2%-5.8pp	28%-6.0pp
Net margin	13.1%-7.8pp	20.9%-1.1pp	22%-3.2pp	25.2%-5.5pp
EBITDA margin	6%-14.4pp	20.4%-2.1pp	22.5%-5.9pp	28.3%-6.5pp
Free cash flow margin	18.6%-10.4pp	29.1%+2.8pp	26.2%-3.6pp	29.8%-15.9pp
Returns
Return on equity	15%-8.8pp	23.8%+2.8pp	21%-2.1pp	23.1%-1.9pp
Return on assets	11.9%-7.4pp	19.3%+1.7pp	17.6%-2.5pp	20.1%-2.5pp
Return on invested capital	8.2%-17.6pp	25.8%+3.1pp	22.6%-4.1pp	26.7%-3.2pp
Efficiency
Asset turnover	0.9×0.0×	0.9×+0.1×	0.8×0.0×	0.8×+0.1×
Inventory turnover	1.8×-0.1×	1.8×+1.2×	0.7×+0.2×	0.5×+0.1×
Liquidity
Current ratio	2.9×-0.4×	3.4×-1.0×	4.4×-2.5×	6.9×+1.3×
Quick ratio	2.9×-0.5×	3.3×-1.0×	4.3×-2.4×	6.7×+1.4×
Cash ratio	0.7×-0.2×	0.9×-0.4×	1.3×+0.4×	0.9×-0.7×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Net debt / EBITDA	-2.5×-1.6×	-0.9×+0.4×	-1.3×-0.7×	-0.6×0.0×
Per Share
Book value per share	$5.40-9.8%	$5.99+32.1%	$4.53+4.8%	$4.33+45.0%
Valuation
Market capitalization	$3.66B-30.7%	$5.28B+57.7%	$3.35B+53.1%	$2.19B-4.4%
Enterprise value	$3.54B-31.3%	$5.16B+60.5%	$3.21B+51.5%	$2.12B-4.0%
Price / earnings	36.7×-0.7×	37.4×+5.8×	31.5×+10.0×	21.6×+1.2×
Price / sales	4.8×-3.0×	7.8×+0.9×	6.9×+1.5×	5.4×-0.8×
Price / book	5.7×-2.1×	7.8×+1.2×	6.6×+2.3×	4.4×-1.7×
EV / EBITDA	77.2×+39.7×	37.4×+7.8×	29.7×+11.0×	18.6×+1.3×
EV / sales	4.7×-3.0×	7.6×+1.0×	6.7×+1.4×	5.3×-0.8×
Free cash flow yield	3.9%+0.2pp	3.7%-0.1pp	3.8%-1.7pp	5.5%-1.8pp
Earnings yield	2.7%0.0pp	2.7%-0.5pp	3.2%-1.5pp	4.6%-0.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Corcept Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Corcept Therapeutics's profit margins?: Corcept Therapeutics (CORT) runs a 98.3% gross margin and a -1.1% operating margin, with a 6.2% net margin.
Where do Corcept Therapeutics's ratios come from?: Every ratio is computed from Corcept Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.